Livzon Pharmaceutical Announces Senior Leadership Reshuffle and Board Changes

The latest announcement is out from Livzon Pharmaceutical Group ( (HK:1513) ).

Livzon Pharmaceutical Group announced that executive director and vice chairman Xu Guoxiang and non-executive director and vice chairman Tao Desheng have resigned upon reaching retirement age, relinquishing all roles in the group and its affiliates. Their departures temporarily leave key board committees below the required membership, prompting the company to move swiftly to elect new directors and committee members in line with Chinese corporate law.

The company also reported that president Tang Yanggang has stepped down from his role as president due to job adjustment but will remain an executive director with positions in subsidiaries, while vice president and financial controller Si Yanxia has retired and resigned from all posts. All four departing executives, who are shareholders, stated they have no disagreements with the board, suggesting an orderly leadership transition that aims to preserve operational stability while the group refreshes its senior management structure.

The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.

More about Livzon Pharmaceutical Group

Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company engaged in the research, development, manufacturing and sale of medicines. The group focuses on prescription drugs and related healthcare products, operating through a network of subsidiaries and associated companies in the domestic market.

YTD Price Performance: 1.82%

Average Trading Volume: 679,748

Technical Sentiment Signal: Buy

Current Market Cap: HK$32.49B

For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.